logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2019 — Nivolumab prolongs survival versus chemotherapy in second-line treatment of metastatic oesophageal squamous cell carcinoma

Final analysis shows modest increase in survival and reduced toxicity compared with chemotherapy.